Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Feb;69(1):65–74. doi: 10.1016/j.curtheres.2008.01.002

Effects of D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia) or the lipidosterolic extract of saw palmetto (Serenoa repens) on the sexual activity in male rats: A controlled, experimental study

Lilia C Fernández 1,1, Rosa Mas 1, Julio Fernández 1, Sarahí Mendoza 1, Rafael Gámez 1, Balia Pardo 1
PMCID: PMC3969950  PMID: 24692784

Abstract

Background: The etiology of benign prostatic hyperplasia (BPH) is not completely understood, but hormonal changes in aging men seem to be pivotal. Dihydrotestosterone, a potent, active metabolite of testosterone, is formed by the enzymatic action of prostate 5α-reductase and causes cell growth and hyperplasia. Consistent with this action, male sexual dysfunction has been clinically documented to be among the drug-related adverse events associated with 5α-reductase inhibitors. The lipidosterolic extract of saw palmetto (LESP) fruit (Serenoa repens) has been used to treat BPH. D-004, a lipid extract of Roystonea regia Royal palm fruit, has been found to prevent prostatic hyperplasia induced by testoste-rone in rodents and to competitively inhibit prostate 5α-reductase activity in vitro.

Objective: The purpose of this study was to assess the effects of D-004 and LESP, administered as single or repeated doses, on the sexual activity in male rats.

Methods: This controlled, experimental study was conducted at the Pharmacology Department, Centre of Natural Products, National Centre for Scientific Research, Havana City, Cuba. Adult male Wistar rats weighing 250 to 300 g were randomized into 5 groups: 2 groups treated orally with D-004 (400 and 800 mg/kg); 2 groups treated orally with LESP (400 and 800 mg/kg); and 1 control group orally administered a water vehicle. Sexual activity behavior (the number of mounts and intromissions, mount latency, and intromission latency) was assessed during 2 observation periods: 90 minutes after the initial dose and at the end of the 30-day treatment. Latency was defined as time elapsed between the first mount and intromission.

Results: A total of 50 rats (mean [SD] age, 10 [3] weeks; mean [SD] weight, 295 [10] g) were included in the experiment. There were no significant difterences in the mean number of mounts, intromissions, mount latency, or intromission latency in the groups treated with single or repeated doses of D-004 or LESP (400 and 800 mg/kg) compared with the controls. There was also no between-group difterence in mating behavior among the active treatment groups. All rats survived up to study completion, with normal behavior (weight gain, food intake, daily observations, without any sign of toxicity). There were no observable adverse events during the study.

Conclusions: D-004 and LESP administered as a single dose or repeated doses for 30 days did not significantly affect male rat sexual activity behavior compared with a vehicle control group.

Key Words: D-004, Roystonea regia, saw palmetto, Serenoa repens, rat mating behavior, rat sexual activity

Full Text

The Full Text of this article is available as a PDF (627.1 KB).

References

  • 1.Clifford GM, Farmer RD. Medical therapy for benign prostatic hyperplasia: A review of the literature. Eur Urol. 2000;38:2–19. doi: 10.1159/000020246. [DOI] [PubMed] [Google Scholar]
  • 2.Simpson RJ. Benign prostatic hyperplasia. An overview of epidemiology and treatment. Prim Care NewHS. 2001:184–186. [Google Scholar]
  • 3.McVary KT. BPH: Epidemiology and comorbidities. Am J Manag Care. 2006;12(Suppl 5):S122–S128. [PubMed] [Google Scholar]
  • 4.Barry MJ, Roehrborn CG. Benign prostatic hyperplasia. BMJ. 2001;323:1042–1046. doi: 10.1136/bmj.323.7320.1042. [published correction appears in BMJ. 2002;324:775] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet. 2003;361:1359–1367. doi: 10.1016/S0140-6736(03)13073-5. [published correction appears in Lancet. 2003;362:496] [DOI] [PubMed] [Google Scholar]
  • 6.Bhargava S, Canda AE, Chapple CR. A rational approach to benign prostatic hyperplasia evaluation: Recent advances. Curr Opin Urol. 2004;14:1–6. doi: 10.1097/00042307-200401000-00001. [DOI] [PubMed] [Google Scholar]
  • 7.Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol. 2000;37:367–380. doi: 10.1159/000020181. [DOI] [PubMed] [Google Scholar]
  • 8.Carson C, III, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61(Suppl 1):2–7. doi: 10.1016/s0090-4295(03)00045-1. [DOI] [PubMed] [Google Scholar]
  • 9.Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia [in German] Urologe A. 2002;41:412–424. doi: 10.1007/s00120-002-0230-2. [DOI] [PubMed] [Google Scholar]
  • 10.Michel MC, Taguchi K, Schafers RS. Alpha 1-adrenoceptor subtypes in the human cardiovascular and urogenital systems. Adv Pharmacol. 1998;42:394–398. doi: 10.1016/s1054-3589(08)60772-3. [DOI] [PubMed] [Google Scholar]
  • 11.Sandhu JS, Te AE. The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data. Curt Urol Rep. 2004;5:274–279. doi: 10.1007/s11934-004-0050-6. [DOI] [PubMed] [Google Scholar]
  • 12.Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-Year follow-up. Urology. 2003;61:354–358. doi: 10.1016/s0090-4295(02)02149-0. [DOI] [PubMed] [Google Scholar]
  • 13.Carraro JC, Raynaud JP, Koch G. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1098 patients. Prostate. 1996;29:231–240. doi: 10.1002/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E. discussion 241–242. [DOI] [PubMed] [Google Scholar]
  • 14.Oelke M, Hofner K, Berges RR, Jonas U. Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results [in German] Urologe A. 2002;41:425–441. doi: 10.1007/s00120-002-0236-9. [DOI] [PubMed] [Google Scholar]
  • 15.Lowe FC, Dreikorn K, Borkowski A. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate. 1998;37:187–193. doi: 10.1002/(sici)1097-0045(19981101)37:3<187::aid-pros8>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  • 16.Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996;9:379–395. doi: 10.2165/00002512-199609050-00008. [DOI] [PubMed] [Google Scholar]
  • 17.Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;3:CD001423. doi: 10.1002/14651858.CD001423. [DOI] [PubMed] [Google Scholar]
  • 18.Aliaev IuG, Vinarov AZ, Lokshin KL, Spivak LG. Five-year experience in treating patients with prostatic hyperplasia permixone (Serenoa repens “Pierre Fabre Medicament”) [in Russian] Urologiia. 2002;1:23–25. [PubMed] [Google Scholar]
  • 19.Debruyne F, Koch G, Boyle P, Groupe d'etude PERMAL Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: A 1-year randomized international study [in French] Prog Urol. 2002;12:384–392. discussion 394. [PubMed] [Google Scholar]
  • 20.Willetts KE, Clements MS, Champion S. Serenoa repens extract for benign prostate hyperplasia: A randomized controlled trial. BJU Int. 2003;92:267–270. doi: 10.1046/j.1464-410x.2003.04316.x. [DOI] [PubMed] [Google Scholar]
  • 21.Bent S, Kane C, Shinohara K. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354:557–566. doi: 10.1056/NEJMoa053085. [DOI] [PubMed] [Google Scholar]
  • 22.Sultan C, Terraza A, Devillier C. Inhibition of androgen metabolism and binding by a liposterolic extract of ‘Serenoa repens B’ in human foreskin fibroblasts. J Steroid Biochem. 1984;20:515–519. doi: 10.1016/0022-4731(84)90264-4. [DOI] [PubMed] [Google Scholar]
  • 23.Weisser H, Tunn S, Behnke B, Krieg M. Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate. 1996;28:300–306. doi: 10.1002/(SICI)1097-0045(199605)28:5<300::AID-PROS5>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  • 24.Iehle CV, Delos S, Guirou O. Human prostatic steroid 5 alpha-reductase isoforms—a comparative study of selective inhibitors. J Steroid Biochem Mol Biol. 1995;54:273–279. doi: 10.1016/0960-0760(95)00134-l. [DOI] [PubMed] [Google Scholar]
  • 25.Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): A 5alpha-reductase types I and II inhibitor—new evidence in a coculture model of BPH. Prostate. 1999;40:232–241. doi: 10.1002/(sici)1097-0045(19990901)40:4<232::aid-pros4>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  • 26.Habib FK, Ross M, Ho CK. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer. 2005;114:190–194. doi: 10.1002/ijc.20701. [DOI] [PubMed] [Google Scholar]
  • 27.Raynaud JP, Cousse H, Martin P-M. Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. J Steroid Biochem Mol Biol. 2002;82:233–239. doi: 10.1016/s0960-0760(02)00187-5. [DOI] [PubMed] [Google Scholar]
  • 28.Zlotta AR, Teillac P, Raynaud JP, Schulman CC. Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), tamsulosin or finasteride. Eur Urol. 2005;48:269–276. doi: 10.1016/j.eururo.2005.03.029. [DOI] [PubMed] [Google Scholar]
  • 29.Perez LY, Menendez R, Mas R, Gonzalez RM. In vitro effect of D-004, a lipid extract of the Cuban royal palm (Roystonea regia), on prostate steroid 5alpha-reductase activity. Curr Ther Res Clin Exp. 2006;67:396–405. doi: 10.1016/j.curtheres.2006.12.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Arruzazabala ML, Carbajal D, Mas R. Preventive effects of D-004, a lipid extract from Cuban royal palm (Roystonea regia) fruits, on testosterone-induced prostate hyperplasia in intact and castrated rodents. Drugs Exp Clin Res. 2004;30:227–233. [PubMed] [Google Scholar]
  • 31.Carbajal D, Arruzazabala ML, Mas R. Effects of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostatic hyptertrophy induced with testosterone or dihydrotestosterone in a rat model: A randomized, controlled study. Curr Ther Res Clin Exp. 2004;65:505–514. doi: 10.1016/j.curtheres.2005.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Noa M, Arruzazabala ML, Carbajal D. Effect of D-004, a lipid extract from Cuban royal palm fruit, on histological changes of prostate hyperplasia induced with testosterone in rats. Int J Tissue React. 2005;27:203–211. [PubMed] [Google Scholar]
  • 33.Carbajal D, Molina V, Mas R, Arruzazabala ML. Therapeutic effect of D-004, a lipid extract from Roystonea regia fruits, on prostate hyperplasia induced in rats. Drugs Exp Clin Res. 2005;31:193–197. [PubMed] [Google Scholar]
  • 34.Srilatha B, Adaikan PG, Arulkumaran S, Ng SC. Sexual dysfunction related to antihypertensive agents: Results from the animal model. Int J Impot Res. 1999;11:107–113. doi: 10.1038/sj.ijir.3900393. [DOI] [PubMed] [Google Scholar]
  • 35.Argiolas A, Melis MR. Central control of penile erection: Role of the paraventricular nucleus of the hypothalamus. Prog Neurobiol. 2005;76:1–21. doi: 10.1016/j.pneurobio.2005.06.002. [DOI] [PubMed] [Google Scholar]
  • 36.Olivier B, Chan JS, Pattij T. Psychopharmacology of male rat sexual behavior: Modeling human sexual dysfunctions? Int J Impot Res. 2006;18(Suppl 1):S14–S23. doi: 10.1038/sj.ijir.3901330. [DOI] [PubMed] [Google Scholar]
  • 37.Ratnasooriya WD, Jayakody JR, Dharmasiri MG. Sodium nitroprusside impairs sexual competence of male rats. Hum Exp Toxicol. 2004;23:187–192. doi: 10.1191/0960327104ht440oa. [DOI] [PubMed] [Google Scholar]
  • 38.Hadidi KA, Aburjai T, Battah AK. A comparative study of Ferula hermonis root extracts and sildenafil on copulatory behaviour of male rats. Fitoterapia. 2003;74:242–246. doi: 10.1016/s0367-326x(03)00032-7. [DOI] [PubMed] [Google Scholar]
  • 39.Khouri NA, El-Akawi Z. Antiandrogenic activity of Ruta graveolens L in male Albino rats with emphasis on sexual and aggressive behavior. Neuro Endocrinol Lett. 2005;26:823–829. [PubMed] [Google Scholar]
  • 40.Qin DN, She BR, She YC, Wang JH. Effects of flavonoids from Semen cuscutae on the reproductive system in male rats. Asian J Androl. 2000;2:99–102. [PubMed] [Google Scholar]
  • 41.Cuban State Drug Control Center . Guidelines for Good Laboratory Practices. CECMED; Cuba: 1992. NC 26-212. [Google Scholar]
  • 42.Nickel JC, Fradet Y, Boake RC. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ. 1996;155:1251–1259. [PMC free article] [PubMed] [Google Scholar]
  • 43.Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: A systematic review of randomised trials. BMC Urol. 2002;2:14. doi: 10.1186/1471-2490-2-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Rhodes L, Primka RL, Berman C. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate. 1993;22:43–51. doi: 10.1002/pros.2990220107. [DOI] [PubMed] [Google Scholar]
  • 45.Carilla E, Briley M, Fauran F. Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem. 1984;20:521–523. doi: 10.1016/0022-4731(84)90265-6. [DOI] [PubMed] [Google Scholar]
  • 46.el-Sheikh MM, Dakkak MR, Saddique A. The effect of Permixon on androgen receptors. Acta Obstet Gynecol Scand. 1988;67:397–399. doi: 10.3109/00016348809004247. [DOI] [PubMed] [Google Scholar]
  • 47.Bombardelli E, Morazzoni P. Serenoa repens (Bartram) JK Small. Fitoterpia. 1997;68:99–113. [Google Scholar]
  • 48.Ribeiro CM, Pereira OC. 5 Alpha-reductase 2 inhibition impairs brain defeminization of male rats: Reproductive aspects. Pharmacol Biochem Behav. 2005;82:228–235. doi: 10.1016/j.pbb.2005.08.015. [DOI] [PubMed] [Google Scholar]
  • 49.Cukierski MA, Sina JL, Prahalada S. Decreased fertility in male rats administered the 5 alpha-reductase inhibitor, finasteride, is due to deficits in copulatory plug formation. Reprod Toxicol. 1991;5:353–362. doi: 10.1016/0890-6238(91)90094-v. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES